Donor‐type red blood cell transfusion to deplete isoagglutinins prior to allogeneic stem cell transplantation from ABO major incompatible bone marrow donors
Summary ABO incompatibility affects approximately 40% of allogeneic stem cell transplants in Caucasian patient populations. Because bone marrow (BM), the preferred graft from paediatric sibling donors and for non‐malignant diseases, has a red blood cell (RBC) content similar to blood, anti‐donor iso...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2023-06, Vol.201 (6), p.1159-1168 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1168 |
|---|---|
| container_issue | 6 |
| container_start_page | 1159 |
| container_title | British journal of haematology |
| container_volume | 201 |
| creator | Jarisch, Andrea Salzmann‐Manrique, Emilia Soerensen, Jan Sach, Gudrun Rettinger, Eva Willasch, Andre Bakhtiar, Shahrzad Klarmann, Dieter Bräuninger, Susanne Moser, Laura Fekadu, Julia Hutter, Martin Klingebiel, Thomas Klusmann, Jan‐Henning Bader, Peter Bonig, Halvard |
| description | Summary
ABO incompatibility affects approximately 40% of allogeneic stem cell transplants in Caucasian patient populations. Because bone marrow (BM), the preferred graft from paediatric sibling donors and for non‐malignant diseases, has a red blood cell (RBC) content similar to blood, anti‐donor isoagglutinins must either be depleted from the recipient or RBCs removed from the graft. To achieve tolerability of unmanipulated BM grafts, we used controlled infusions of donor ABO‐type RBC units to deplete isoagglutinins before the transplant. This retrospective study evaluates the outcomes of 52 ABO major incompatible BM transplants performed at our centre between 2007 and 2019. The use of donor‐type RBC transfusions was well tolerated. They effectively reduced isoagglutinins levels, typically achieving target titres after one (60%) or two (29%) transfusions. The approach allowed for successful and uneventful infusions of unmanipulated BM which provided timely engraftment. The transplant outcomes were not inferior to those of a matched‐pair control group of patients with ABO‐identical donors. |
| doi_str_mv | 10.1111/bjh.18761 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2790048092</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2790048092</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3881-56fcc6311efa59be36f68410ac856f45e30c918998c43e060b47c9ee35f738ca3</originalsourceid><addsrcrecordid>eNp1kU1u1TAUhS0Eoo_CgA0gS0zKIK1vnDj2sD9AQZU6gXHkODePPDl2sB1Vb8YSWEEXx0pweAUhJDyx5PP56Nx7CHkJ7BTyOet2X05BNgIekQ1wURclVPCYbBhjTQGskkfkWYw7xoCzGp6SIy5UpQSDDbm_8s6HH9--p_2MNGBPO-t9Tw1aS1PQLg5LHL2jydMeZ4sJ6Ri93m7tkkY3ukjnMPqw6tpav0WHo6Ex4fSXx2y1SzqtPkPwEz2_uKWT3uVvozN-mrPUWaSdd5jfQ_B3tF9zxefkyaBtxBcP9zH5_O7tp8vr4ub2_YfL85vCcCmhqMVgjOAAOOhadcjFIGQFTBuZpapGzowCqZQ0FUcmWFc1RiHyemi4NJofk5OD7xz81wVjaqcxrvm1Q7_EtmwUy3tkqszo63_QnV-Cy-naUpYlQKOUytSbA2WCjzHg0OY15dH2LbB2La3NpbW_SsvsqwfHpZuw_0P-bikDZwfgbrS4_79Te_Hx-mD5E5m_pH0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2822117999</pqid></control><display><type>article</type><title>Donor‐type red blood cell transfusion to deplete isoagglutinins prior to allogeneic stem cell transplantation from ABO major incompatible bone marrow donors</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Free Content</source><creator>Jarisch, Andrea ; Salzmann‐Manrique, Emilia ; Soerensen, Jan ; Sach, Gudrun ; Rettinger, Eva ; Willasch, Andre ; Bakhtiar, Shahrzad ; Klarmann, Dieter ; Bräuninger, Susanne ; Moser, Laura ; Fekadu, Julia ; Hutter, Martin ; Klingebiel, Thomas ; Klusmann, Jan‐Henning ; Bader, Peter ; Bonig, Halvard</creator><creatorcontrib>Jarisch, Andrea ; Salzmann‐Manrique, Emilia ; Soerensen, Jan ; Sach, Gudrun ; Rettinger, Eva ; Willasch, Andre ; Bakhtiar, Shahrzad ; Klarmann, Dieter ; Bräuninger, Susanne ; Moser, Laura ; Fekadu, Julia ; Hutter, Martin ; Klingebiel, Thomas ; Klusmann, Jan‐Henning ; Bader, Peter ; Bonig, Halvard</creatorcontrib><description>Summary
ABO incompatibility affects approximately 40% of allogeneic stem cell transplants in Caucasian patient populations. Because bone marrow (BM), the preferred graft from paediatric sibling donors and for non‐malignant diseases, has a red blood cell (RBC) content similar to blood, anti‐donor isoagglutinins must either be depleted from the recipient or RBCs removed from the graft. To achieve tolerability of unmanipulated BM grafts, we used controlled infusions of donor ABO‐type RBC units to deplete isoagglutinins before the transplant. This retrospective study evaluates the outcomes of 52 ABO major incompatible BM transplants performed at our centre between 2007 and 2019. The use of donor‐type RBC transfusions was well tolerated. They effectively reduced isoagglutinins levels, typically achieving target titres after one (60%) or two (29%) transfusions. The approach allowed for successful and uneventful infusions of unmanipulated BM which provided timely engraftment. The transplant outcomes were not inferior to those of a matched‐pair control group of patients with ABO‐identical donors.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.18761</identifier><identifier>PMID: 36949601</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>ABO Blood-Group System ; ABO mismatch ; ABO system ; Allografts ; alloHSCT ; Blood ; Blood Group Incompatibility ; Blood transfusion ; Bone Marrow ; Bone marrow transplantation ; Bone Marrow Transplantation - adverse effects ; Child ; donor‐type red blood cell transfusion ; Erythrocyte Transfusion - adverse effects ; Erythrocytes ; Hematology ; Hematopoietic Stem Cell Transplantation - adverse effects ; Humans ; paediatric transplantation ; recipient isoagglutinins ; Red-Cell Aplasia, Pure - etiology ; Retrospective Studies ; Stem cell transplantation ; Stem cells ; Transplants & implants</subject><ispartof>British journal of haematology, 2023-06, Vol.201 (6), p.1159-1168</ispartof><rights>2023 The Authors. published by British Society for Haematology and John Wiley & Sons Ltd.</rights><rights>2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.</rights><rights>2023. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3881-56fcc6311efa59be36f68410ac856f45e30c918998c43e060b47c9ee35f738ca3</citedby><cites>FETCH-LOGICAL-c3881-56fcc6311efa59be36f68410ac856f45e30c918998c43e060b47c9ee35f738ca3</cites><orcidid>0000-0003-2508-1145 ; 0000-0002-1241-5137 ; 0000-0003-0088-2675 ; 0000-0003-1639-2697 ; 0000-0002-1070-0727 ; 0000-0002-9898-1542</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.18761$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.18761$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,777,781,1412,1428,27905,27906,45555,45556,46390,46814</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36949601$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jarisch, Andrea</creatorcontrib><creatorcontrib>Salzmann‐Manrique, Emilia</creatorcontrib><creatorcontrib>Soerensen, Jan</creatorcontrib><creatorcontrib>Sach, Gudrun</creatorcontrib><creatorcontrib>Rettinger, Eva</creatorcontrib><creatorcontrib>Willasch, Andre</creatorcontrib><creatorcontrib>Bakhtiar, Shahrzad</creatorcontrib><creatorcontrib>Klarmann, Dieter</creatorcontrib><creatorcontrib>Bräuninger, Susanne</creatorcontrib><creatorcontrib>Moser, Laura</creatorcontrib><creatorcontrib>Fekadu, Julia</creatorcontrib><creatorcontrib>Hutter, Martin</creatorcontrib><creatorcontrib>Klingebiel, Thomas</creatorcontrib><creatorcontrib>Klusmann, Jan‐Henning</creatorcontrib><creatorcontrib>Bader, Peter</creatorcontrib><creatorcontrib>Bonig, Halvard</creatorcontrib><title>Donor‐type red blood cell transfusion to deplete isoagglutinins prior to allogeneic stem cell transplantation from ABO major incompatible bone marrow donors</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
ABO incompatibility affects approximately 40% of allogeneic stem cell transplants in Caucasian patient populations. Because bone marrow (BM), the preferred graft from paediatric sibling donors and for non‐malignant diseases, has a red blood cell (RBC) content similar to blood, anti‐donor isoagglutinins must either be depleted from the recipient or RBCs removed from the graft. To achieve tolerability of unmanipulated BM grafts, we used controlled infusions of donor ABO‐type RBC units to deplete isoagglutinins before the transplant. This retrospective study evaluates the outcomes of 52 ABO major incompatible BM transplants performed at our centre between 2007 and 2019. The use of donor‐type RBC transfusions was well tolerated. They effectively reduced isoagglutinins levels, typically achieving target titres after one (60%) or two (29%) transfusions. The approach allowed for successful and uneventful infusions of unmanipulated BM which provided timely engraftment. The transplant outcomes were not inferior to those of a matched‐pair control group of patients with ABO‐identical donors.</description><subject>ABO Blood-Group System</subject><subject>ABO mismatch</subject><subject>ABO system</subject><subject>Allografts</subject><subject>alloHSCT</subject><subject>Blood</subject><subject>Blood Group Incompatibility</subject><subject>Blood transfusion</subject><subject>Bone Marrow</subject><subject>Bone marrow transplantation</subject><subject>Bone Marrow Transplantation - adverse effects</subject><subject>Child</subject><subject>donor‐type red blood cell transfusion</subject><subject>Erythrocyte Transfusion - adverse effects</subject><subject>Erythrocytes</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Humans</subject><subject>paediatric transplantation</subject><subject>recipient isoagglutinins</subject><subject>Red-Cell Aplasia, Pure - etiology</subject><subject>Retrospective Studies</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Transplants & implants</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kU1u1TAUhS0Eoo_CgA0gS0zKIK1vnDj2sD9AQZU6gXHkODePPDl2sB1Vb8YSWEEXx0pweAUhJDyx5PP56Nx7CHkJ7BTyOet2X05BNgIekQ1wURclVPCYbBhjTQGskkfkWYw7xoCzGp6SIy5UpQSDDbm_8s6HH9--p_2MNGBPO-t9Tw1aS1PQLg5LHL2jydMeZ4sJ6Ri93m7tkkY3ukjnMPqw6tpav0WHo6Ex4fSXx2y1SzqtPkPwEz2_uKWT3uVvozN-mrPUWaSdd5jfQ_B3tF9zxefkyaBtxBcP9zH5_O7tp8vr4ub2_YfL85vCcCmhqMVgjOAAOOhadcjFIGQFTBuZpapGzowCqZQ0FUcmWFc1RiHyemi4NJofk5OD7xz81wVjaqcxrvm1Q7_EtmwUy3tkqszo63_QnV-Cy-naUpYlQKOUytSbA2WCjzHg0OY15dH2LbB2La3NpbW_SsvsqwfHpZuw_0P-bikDZwfgbrS4_79Te_Hx-mD5E5m_pH0</recordid><startdate>202306</startdate><enddate>202306</enddate><creator>Jarisch, Andrea</creator><creator>Salzmann‐Manrique, Emilia</creator><creator>Soerensen, Jan</creator><creator>Sach, Gudrun</creator><creator>Rettinger, Eva</creator><creator>Willasch, Andre</creator><creator>Bakhtiar, Shahrzad</creator><creator>Klarmann, Dieter</creator><creator>Bräuninger, Susanne</creator><creator>Moser, Laura</creator><creator>Fekadu, Julia</creator><creator>Hutter, Martin</creator><creator>Klingebiel, Thomas</creator><creator>Klusmann, Jan‐Henning</creator><creator>Bader, Peter</creator><creator>Bonig, Halvard</creator><general>Blackwell Publishing Ltd</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2508-1145</orcidid><orcidid>https://orcid.org/0000-0002-1241-5137</orcidid><orcidid>https://orcid.org/0000-0003-0088-2675</orcidid><orcidid>https://orcid.org/0000-0003-1639-2697</orcidid><orcidid>https://orcid.org/0000-0002-1070-0727</orcidid><orcidid>https://orcid.org/0000-0002-9898-1542</orcidid></search><sort><creationdate>202306</creationdate><title>Donor‐type red blood cell transfusion to deplete isoagglutinins prior to allogeneic stem cell transplantation from ABO major incompatible bone marrow donors</title><author>Jarisch, Andrea ; Salzmann‐Manrique, Emilia ; Soerensen, Jan ; Sach, Gudrun ; Rettinger, Eva ; Willasch, Andre ; Bakhtiar, Shahrzad ; Klarmann, Dieter ; Bräuninger, Susanne ; Moser, Laura ; Fekadu, Julia ; Hutter, Martin ; Klingebiel, Thomas ; Klusmann, Jan‐Henning ; Bader, Peter ; Bonig, Halvard</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3881-56fcc6311efa59be36f68410ac856f45e30c918998c43e060b47c9ee35f738ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>ABO Blood-Group System</topic><topic>ABO mismatch</topic><topic>ABO system</topic><topic>Allografts</topic><topic>alloHSCT</topic><topic>Blood</topic><topic>Blood Group Incompatibility</topic><topic>Blood transfusion</topic><topic>Bone Marrow</topic><topic>Bone marrow transplantation</topic><topic>Bone Marrow Transplantation - adverse effects</topic><topic>Child</topic><topic>donor‐type red blood cell transfusion</topic><topic>Erythrocyte Transfusion - adverse effects</topic><topic>Erythrocytes</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Humans</topic><topic>paediatric transplantation</topic><topic>recipient isoagglutinins</topic><topic>Red-Cell Aplasia, Pure - etiology</topic><topic>Retrospective Studies</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jarisch, Andrea</creatorcontrib><creatorcontrib>Salzmann‐Manrique, Emilia</creatorcontrib><creatorcontrib>Soerensen, Jan</creatorcontrib><creatorcontrib>Sach, Gudrun</creatorcontrib><creatorcontrib>Rettinger, Eva</creatorcontrib><creatorcontrib>Willasch, Andre</creatorcontrib><creatorcontrib>Bakhtiar, Shahrzad</creatorcontrib><creatorcontrib>Klarmann, Dieter</creatorcontrib><creatorcontrib>Bräuninger, Susanne</creatorcontrib><creatorcontrib>Moser, Laura</creatorcontrib><creatorcontrib>Fekadu, Julia</creatorcontrib><creatorcontrib>Hutter, Martin</creatorcontrib><creatorcontrib>Klingebiel, Thomas</creatorcontrib><creatorcontrib>Klusmann, Jan‐Henning</creatorcontrib><creatorcontrib>Bader, Peter</creatorcontrib><creatorcontrib>Bonig, Halvard</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jarisch, Andrea</au><au>Salzmann‐Manrique, Emilia</au><au>Soerensen, Jan</au><au>Sach, Gudrun</au><au>Rettinger, Eva</au><au>Willasch, Andre</au><au>Bakhtiar, Shahrzad</au><au>Klarmann, Dieter</au><au>Bräuninger, Susanne</au><au>Moser, Laura</au><au>Fekadu, Julia</au><au>Hutter, Martin</au><au>Klingebiel, Thomas</au><au>Klusmann, Jan‐Henning</au><au>Bader, Peter</au><au>Bonig, Halvard</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Donor‐type red blood cell transfusion to deplete isoagglutinins prior to allogeneic stem cell transplantation from ABO major incompatible bone marrow donors</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2023-06</date><risdate>2023</risdate><volume>201</volume><issue>6</issue><spage>1159</spage><epage>1168</epage><pages>1159-1168</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Summary
ABO incompatibility affects approximately 40% of allogeneic stem cell transplants in Caucasian patient populations. Because bone marrow (BM), the preferred graft from paediatric sibling donors and for non‐malignant diseases, has a red blood cell (RBC) content similar to blood, anti‐donor isoagglutinins must either be depleted from the recipient or RBCs removed from the graft. To achieve tolerability of unmanipulated BM grafts, we used controlled infusions of donor ABO‐type RBC units to deplete isoagglutinins before the transplant. This retrospective study evaluates the outcomes of 52 ABO major incompatible BM transplants performed at our centre between 2007 and 2019. The use of donor‐type RBC transfusions was well tolerated. They effectively reduced isoagglutinins levels, typically achieving target titres after one (60%) or two (29%) transfusions. The approach allowed for successful and uneventful infusions of unmanipulated BM which provided timely engraftment. The transplant outcomes were not inferior to those of a matched‐pair control group of patients with ABO‐identical donors.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>36949601</pmid><doi>10.1111/bjh.18761</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-2508-1145</orcidid><orcidid>https://orcid.org/0000-0002-1241-5137</orcidid><orcidid>https://orcid.org/0000-0003-0088-2675</orcidid><orcidid>https://orcid.org/0000-0003-1639-2697</orcidid><orcidid>https://orcid.org/0000-0002-1070-0727</orcidid><orcidid>https://orcid.org/0000-0002-9898-1542</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2023-06, Vol.201 (6), p.1159-1168 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2790048092 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Free Content |
| subjects | ABO Blood-Group System ABO mismatch ABO system Allografts alloHSCT Blood Blood Group Incompatibility Blood transfusion Bone Marrow Bone marrow transplantation Bone Marrow Transplantation - adverse effects Child donor‐type red blood cell transfusion Erythrocyte Transfusion - adverse effects Erythrocytes Hematology Hematopoietic Stem Cell Transplantation - adverse effects Humans paediatric transplantation recipient isoagglutinins Red-Cell Aplasia, Pure - etiology Retrospective Studies Stem cell transplantation Stem cells Transplants & implants |
| title | Donor‐type red blood cell transfusion to deplete isoagglutinins prior to allogeneic stem cell transplantation from ABO major incompatible bone marrow donors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T20%3A44%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Donor%E2%80%90type%20red%20blood%20cell%20transfusion%20to%20deplete%20isoagglutinins%20prior%20to%20allogeneic%20stem%20cell%20transplantation%20from%20ABO%20major%20incompatible%20bone%20marrow%20donors&rft.jtitle=British%20journal%20of%20haematology&rft.au=Jarisch,%20Andrea&rft.date=2023-06&rft.volume=201&rft.issue=6&rft.spage=1159&rft.epage=1168&rft.pages=1159-1168&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.18761&rft_dat=%3Cproquest_cross%3E2790048092%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2822117999&rft_id=info:pmid/36949601&rfr_iscdi=true |